Sacituzumab Tirumotecan for Renal Medullary Carcinoma

Overseen By Pavlos Msaouel, MD

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: M.D. Anderson Cancer Center

Must not be taking: Topoisomerase inhibitors, TROP2-targeted ADCs

Disqualifiers: Other malignancies, Uncontrolled infections, Severe heart conditions, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: 18 weeks

What You Need to Know Before You Apply

What is the purpose of this trial?

To learn if sacituzumab tirumotecan can help to control advanced or metastatic SMARCB1-deficient RMC in patients whose disease has progressed after receiving at least 1 treatment.

Who Is on the Research Team?

Pavlos Msaouel, MD

Principal Investigator

M.D. Anderson Cancer Center

Are You a Good Fit for This Trial?

Inclusion Criteria

I am at least 18 years old.

I have tried at least one previous treatment, but my disease has worsened.

I use a wheelchair but can move around independently.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive sacituzumab tirumotecan for advanced or metastatic SMARCB1-deficient RMC

18 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Long-term follow-up

Monitoring for safety and adverse events through study completion

1 year

What Are the Treatments Tested in This Trial?

Interventions

• Sacituzumab Tirumotecan

How Is the Trial Designed?

Group I: Single Arm Experimental Treatment 1 Intervention

Treatment with Sacituzumab Tirumotecan

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials

3,107

Recruited

1,813,000+

Merck Sharp & Dohme LLC

Industry Sponsor

Trials

4,096

Recruited

5,232,000+

Chirfi Guindo

Merck Sharp & Dohme LLC

Chief Marketing Officer since 2022

Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business

Robert M. Davis

Merck Sharp & Dohme LLC

Chief Executive Officer since 2021

JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University